Form 8-K - Current report:
SEC Accession No. 0002023658-25-000107
Filing Date
2025-11-10
Accepted
2025-11-10 07:32:31
Documents
14
Period of Report
2025-11-10
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K bcax-20251110.htm   iXBRL 8-K 26518
2 EX-99.1 pressreleaseq32025.htm EX-99.1 93240
6 BICARA LOGO bicaralogoa.jpg GRAPHIC 6820
  Complete submission text file 0002023658-25-000107.txt   262943

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT bcax-20251110.xsd EX-101.SCH 1779
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT bcax-20251110_lab.xml EX-101.LAB 23435
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT bcax-20251110_pre.xml EX-101.PRE 13579
16 EXTRACTED XBRL INSTANCE DOCUMENT bcax-20251110_htm.xml XML 2910
Mailing Address 116 HUNTINGTON AVENUE SUITE 703 BOSTON MA 02116
Business Address 116 HUNTINGTON AVENUE SUITE 703 BOSTON MA 02116 617-468-4219
Bicara Therapeutics Inc. (Filer) CIK: 0002023658 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-42271 | Film No.: 251464353
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)